文献速递垂体与肾上腺疾病

库欣综合征的生化控制:大型单中心队列的治疗结局

Biochemical Control in Cushing's Syndrome: Outcomes of the Treatment in a Large Single Center Cohort.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该单中心回顾性分析纳入296例确诊库欣综合征患者(185例库欣病、27例异位库欣综合征、84例肾上腺库欣综合征),评估生化控制率。一线治疗使82%患者获得生化控制;库欣病获得控制的时间较长且持续或复发更常见;2013年后诊断的库欣病患者高皮质醇总时间较短;末次随访时肾上腺库欣综合征94%、异位库欣综合征100%、库欣病92%获得控制。

要点

  • 一线治疗使82%的库欣综合征患者获得生化控制。
  • 库欣病获得生化控制的中位时间长于肾上腺和异位库欣综合征。
  • 库欣病一线治疗后持续或复发较异位和肾上腺库欣综合征更常见。

核心结论

  • 不同亚型库欣综合征多数患者可在合理时间范围内获得生化控制,且高皮质醇控制随时间改善。

研究设计与样本

  • 单中心回顾性分析,纳入确诊库欣综合征患者296例(库欣病185例、异位库欣综合征27例、肾上腺库欣综合征84例,含单侧和双侧)。

主要发现

  • 一线治疗使82%的患者获得生化控制。
  • 获得生化控制的中位时间(四分位距):库欣病11.0周(5.6-29.8),长于肾上腺库欣综合征7.7周(4.1-17.1)和异位库欣综合征5.6周(4.1-23.3),P < .05。
  • 一线治疗后疾病持续或复发:库欣病分别为24%和18%,高于异位库欣综合征的15%和15%及肾上腺库欣综合征的6%和4%,P < .05。
  • 自诊断以来高皮质醇总时间:2013年后诊断的库欣病患者为13.5周,短于2013年前诊断者的26.1周,P < .0070。
  • 末次随访(中位76个月,四分位距38-163)时生化控制率:肾上腺库欣综合征94%、异位库欣综合征100%、库欣病92%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Normalization of hypercortisolism is essential to reduce morbidity and mortality in patients with Cushing's syndrome (CS). The aim of this analysis was to assess biochemical control rates in patients with Cushing's disease (CD), ectopic Cushing's syndrome (ECS), and adrenal Cushing's syndrome (ACS). METHODS: Patients with confirmed CS (n = 296) treated in a single tertiary care center were retrospectively analyzed (185 CD, 27 ECS, 84 uni- and bilateral ACS). RESULTS: First-line treatment led to biochemical control in 82% of the patients. Time to biochemical control (median, interquartile range) was longer in CD (11.0 weeks, 5.6-29.8; P < .05) than in ACS (7.7 weeks, 4.1-17.1) and ECS (5.6 weeks, 4.1-23.3). Disease persistence or recurrence after first-line therapy was observed more often in CD (24% and 18%; P < .05) than in ECS (15% and 15%) and ACS (6% and 4%). Total time in hypercortisolism since diagnosis was significantly shorter in patients with CD diagnosed since 2013, after specialized patient care was implemented, compared to patients diagnosed before 2013 (13.5 weeks vs 26.1 weeks; P < .0070). Control of hypercortisolism at last follow-up (76 months, 38-163) was achieved in 94% of patients with ACS, 100% of patients with ECS, and 92% of patients with CD. CONCLUSION: Biochemical control can be achieved in most patients with different subtypes of CS within a reasonable time frame. Control of hypercortisolism has improved over time.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ritzel K, Fazel J, August L, et al. Biochemical Control in Cushing's Syndrome: Outcomes of the Treatment in a Large Single Center Cohort. J Clin Endocrinol Metab. 2025. PMID: 38767080. doi:10.1210/clinem/dgae337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。